The cardioprotective effects of sEH inhibitors are gradually expanding therapeutically toward renal diseases, including hypertension, diabetic nephropathy, drug-induced nephrotoxicity, and renal fibrotic disease [73]. This evidence concerns the gene EPHX2 and kidney disorder.